A Phase 1 interventional study of STSA-1002 Injection and Placebo in Healthy Subject, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects. A total of 26 healthy subjects were enrolled in three dosage groups.
Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will be randomized to receive low dose of STSA-1002 or dose-matched placebo.
Drug: STSA-1002 Injection · Drug: Placebo
All subjects will be randomized to receive middle dose of STSA-1002 or dose-matched placebo.
Drug: STSA-1002 Injection · Drug: Placebo
All subjects will be randomized to receive high dose of STSA-1002 or dose-matched placebo.
Drug: STSA-1002 Injection · Drug: Placebo
Intravenous injection
Intravenous injection
Incidence of Adverse Events、Clinically Significant Laboratory Abnormalities、Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.
To evaluate the safety and tolerability of multiple intravenous administration of STSA-1002 in healthy adult subjects.
Time frame: Up to Study Day 56
Maximum plasma concentration (Cmax)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Time of maximum concentration (Tmax)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Elimination half-life (t1/2)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Mean residence time (MRT)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Clearance (CL)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Apparent volume of distribution (Vz)
To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Maximum Concentration of the Analyte in Plasma at steady state(Cmax, ss)
To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Minimum Measured Concentration of the Analyte in Plasma at Steady State(Cmin, ss)
To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Time-averaged concentration at steady state(Cav, ss)
To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Area under the concentration curve from time 0 extrapolate to infinite time(AUCinf,ss)
To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Degree of fluctuation(DF)
To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Accumulation factor
To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects
Time frame: From Day 0 to Day 56
Change from baseline in concentration of free C5a and anti-drug antibody
To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 in healthy subjects
Time frame: From Day 0 to Day 56
Change from baseline in concentration of Myeloperoxidase(MPO)、Neutrophil elastase(NE)、Proteinase3(PR3)、 C-X-C chemokine receptor 1(CXCR1)
To evaluate the effect of STSA-1002 on MPO、NE、PR3、CXCR1
Time frame: From Day 0 to Day 56
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Apr 2023, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Greziprubart
Staidson (Beijing) Biopharmaceuticals Co., Ltd →